Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACEi vs SGLT2i in Diabetic Kidney Disease
NCT06187493Not yet recruiting
- Sponsor
- Assiut University
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of dapagliflozin and empagliflozin in diabetic kidney disease (DKD) (2 arms), sponsored by Assiut University. Primary endpoint: Prevention of the development of DKD and alter its natural progression at 1 year. Planned start Jan 2024; status: not yet recruiting.
02
Drugs
dapagliflozinempagliflozin
03
Conditions
diabetic kidney disease (DKD)
Beyond the preview
Go deeper on NCT06187493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06187493.